AbbVie advances clinical program of upadacitinib in SLE to Phase 3

AbbVie announced topline results from a Phase 2 study of upadacitinib given alone or as combination therapy with a Bruton’s Tyrosine Kinase inhibitor, once daily in patients with moderately to severely active systemic lupus erythematosus. The SLEek study met the primary endpoint of SLE Responder Index and steroid dose less than or equal to 10 mg prednisone equivalent once per day at week 24 in the upadacitinib 30 mg group. Based on the results, AbbVie is advancing its clinical program of upadacitinib in SLE to Phase 3.